Latest Conference Articles

With a lot of the attention in multiple sclerosis care turning to finding treatments for progressive forms of the disease those who suffer relapses are in some ways being left in the shadows of treatment discoveries and care.

A recently concluded survey looked at issues most affecting patients with multiple sclerosis that they may not have been willing or able to discuss with health care providers but could help others with the condition in the future.

New medications are constantly being developed and approved for the treatment of multiple sclerosis. How those treatments are used and what the future holds for the disease remains to be seen.

There are known differences between men and women when it comes to multiple sclerosis and the likelihood of developing the disease. There are also differences in how best to treat patients given their gender.

In a chronic condition where depression is a known symptom treating the mental condition of a patient can be just as important as the physical aspects especially when suicide prevention is part of the overall care.

Defining what advanced disease means in multiple sclerosis is a topic open for discussion. Deciding a course of treatment after that determination is another challenge in overall patient care.

Even as the number of medications approved to treat relapsing remitting multiple sclerosis continues to grow patients with progressive forms of the condition still await the first approved treatment option to help manage their symptoms.

While it may not be possible to compare the efficacy of treatments for multiple sclerosis in clinical trials work is being done to look at the various options through results in actual practice.

Research into the inner workings of multiple sclerosis comes in all shapes and sizes including looking at specific parts of the brain. A recent study has looked at the role of the blood brain barrier and how it affects patients with this condition.

There are conferences held all over the world working to improve treatment of multiple sclerosis. The consortium of Multiple Sclerosis Centers is one that takes a different approach to this condition.

Individual trials have shown various benefits associated with fingolimod (Gilenya) for relapsing-remitted multiple sclerosis (RRMS), but its consistency across studies has not been fully understood.

Fingolimod (Gilenya) is an immunosuppressant used to treat multiple sclerosis, but improvements with disability have been unsteady with this drug.

Country music artist, Clay Walker – who is well-known for his hit songs “She Won’t Be Lonely Long†and “Live Until I Die" – was diagnosed with a relapsing form of multiple sclerosis (MS) at the age of 26.

“Disabled people aren’t sexually attractive†is just one real quote – and myth – from someone living with multiple sclerosis.

While newly approved treatments for multiple sclerosis move away from interferon based medications Rebif continues to be a popular choice after more than a decade in the field.

The treatment of multiple sclerosis requires the work of more than just neurologists and that figures to be the case well into the future as well.

Throughout medicine personalized care is becoming an increasing focus of the field. This is no exception for the treatment of multiple sclerosis where patients may find a medication which works for a short time before needing to find a new option.

Marijuana and alcohol – studies suggest that one of these substances helps patients with multiple sclerosis while the other can contribute to comorbidities.

Lifestyle factors and multiple sclerosis is a two-way street; but what does that mean for practicing physicians? Allen Bowling, MD, PhD, explains at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis Center (CMSC) in National Harbor, Maryland.

Perfecting an exercise regimen on an individual basis for people with multiple sclerosis is no easy task, as described at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis Center (CMSC) in National Harbor, Maryland.

A change in appetite may not be a huge red flag in most people, but in patients with multiple sclerosis, it could have a larger meaning.

To date, there is no treatment approved by the US Food and Drug Administration (FDA) for primary progressive multiple sclerosis. But a promising treatment could change that regardless of apparent skin reactions.

Disease-modifying therapies (DMTs) help reduce relapses in people with multiple sclerosis. While options have expanded, little is known about which one has the greatest effectiveness.

A phase III study that examined teriflunomide (Aubagio) in a subtype of patients with multiple sclerosis was presented at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis Center (CMSC) in National Harbor, Maryland.

There are various disease-modifying treatment (DMT) options for patients with relapsing-remitting multiple sclerosis (RRMS). But how much do neurologists and patients agree on the first-line course?

Ophthalmology has made great strides in recent years treating many of the more commonly seen conditions, but work is being done to address some of the more rare problems, as well.

Even a decade ago the technology used in diagnosis for ophthalmology was still developing. In that time work has been done to improve the ways doctors can see the potential problems their patients may have to provide a higher level of care.

A condition like chronic traumatic encephalopathy is only able to be diagnosed now after a patient has already died. New technology is being developed to help patients while they are still alive. These new techniques could also be used to help other conditions as well.

For more than a decade medical researchers have been learning more about their fields from studying the injuries sustained by soldiers on the battlefield. A recent study looked at vision loss in this patient population, particularly in regards to traumatic brain injury.

While cataracts may be one of the most common conditions being treated the National Eye Institute is also looking at ways to treat other less commonly seen issues as well.